Valo Therapeutics Oy has secured €19 million in investment funding to advance clinical trials of its cancer immunotherapy, PeptiCRAd, supported by major investors Indaco Venture Partners and CDP Venture Capital.
Target Company Overview
Valo Therapeutics Oy, based in Finland, is a pioneering biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company's flagship offering, PeptiCRAd, utilizes tumor antigen-coated oncolytic viruses to enhance the body's immune response against solid tumors. Founded by Professor Vincenzo Cerullo, who hails from Naples, Valo is positioned at the forefront of cancer research and therapeutics, aiming to transform treatment paradigms for diverse cancer types.
The recent acquisition of €19 million in funding marks a significant milestone for Valo Therapeutics, facilitating the clinical development of PeptiCRAd. This capital will specifically aid in expanding the Phase 1B clinical trials, which will be conducted across Italy, Australia, and Germany, delineating a robust approach to combating cancer.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Italy
Italy's biotechnology landscape is experiencing rapid growth, underpinned by increasing investments and an expanding pool of talented researchers. The Italian biotech sector is recognized for its strong emphasis on addressing unme
Similar Deals
Maki.vc, Firstminute Capital, Springvest, Ilmastorahasto, Finnvera, Business Finland, Norion Bank, Etelä-Pohjanmaan ELY-keskus → Volare
2025
Evolver Fund II → Repolar Pharmaceuticals
2024
Indaco Venture Partners, CDP Venture Capital SGR, Fondazione ENEA Tech e Biomedical
invested in
Valo Therapeutics Oy
in 2025
in a Other VC deal
Disclosed details
Transaction Size: $20M